Skip to main content
PMC home page
Archives of Disease in Childhood logoLink to Archives of Disease in Childhood
. 1984 Nov;59(11):1020–1026. doi: 10.1136/adc.59.11.1020

Prostaglandin E1 in suspected ductus dependent cardiac malformation.

K A Hallidie-Smith
PMCID: PMC1628837  PMID: 6542338

Abstract

Fifty two sick neonates with major duct dependent cardiac defects were given short term intravenous infusions of prostaglandin E1 (alprostadil) in doses varying between 0.005 and 0.1 micrograms/kg/minute. The object of the study was to try to achieve an effective but safe regiment that could be instituted as soon as such a diagnosis was suspected. Effective clinical improvement was achieved at each dosage but the incidence of side effects seemed to be dose related, and no serious side effects were noted at a dosage of 0.005 to 0.01 micrograms/kg/minute. It is recommended that a low dosage regimen be started before transfer to a paediatric cardiac centre.

Full text

PDF
1020

Images in this article

1022Fig. 4
on p.1022

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Awan N. A., Evenson M. K., Needham K. E., Beattie J. M., Amsterdam E. A., Mason D. T. Cardiocirculatory and myocardial energetic effects of prostaglandin E1 in severe left ventricular failure due to chronic coronary heart disease. Am Heart J. 1981 Oct;102(4):703–709. doi: 10.1016/0002-8703(81)90095-8. [DOI] [PubMed] [Google Scholar]
  2. Beitzke A., Suppan C. H. Use of prostaglandin E2 in management of transposition of great arteries before balloon atrial septostomy. Br Heart J. 1983 Apr;49(4):341–344. doi: 10.1136/hrt.49.4.341. [DOI] [PMC free article] [PubMed] [Google Scholar]
  3. Carlson L. A., Ekelund L. G., Orö L. Circulatory and respiratory effects of different doses of prostaglandin E1 in man. Acta Physiol Scand. 1969 Jan-Feb;75(1):161–169. doi: 10.1111/j.1748-1716.1969.tb04368.x. [DOI] [PubMed] [Google Scholar]
  4. Clyman R. I., Heymann M. A., Rudolph A. M. Ductus arteriosus responses to prostaglandin E1 at high and low oxygen concentrations. Prostaglandins. 1977 Feb;13(2):219–223. doi: 10.1016/0090-6980(77)90003-x. [DOI] [PubMed] [Google Scholar]
  5. Clyman R. I., Mauray F., Roman C., Heymann M. A., Payne B. Factors determining the loss of ductus arteriosus responsiveness to prostaglandin E. Circulation. 1983 Aug;68(2):433–436. doi: 10.1161/01.cir.68.2.433. [DOI] [PubMed] [Google Scholar]
  6. Coceani F., Olley P. M., Lock J. E. Prostaglandins, ductus arteriosus, pulmonary circulation: current concepts and clinical potential. Eur J Clin Pharmacol. 1980 Jul;18(1):75–81. doi: 10.1007/BF00561482. [DOI] [PubMed] [Google Scholar]
  7. Fariello R., Olley P. M., Coceani F. Neurological and electroencephalographic changes in newborns treated with prostaglandins E1 and E2. Prostaglandins. 1977 May;13(5):901–907. doi: 10.1016/0090-6980(77)90219-2. [DOI] [PubMed] [Google Scholar]
  8. Freed M. D., Heymann M. A., Lewis A. B., Roehl S. L., Kensey R. C. Prostaglandin E1 infants with ductus arteriosus-dependent congenital heart disease. Circulation. 1981 Nov;64(5):899–905. doi: 10.1161/01.cir.64.5.899. [DOI] [PubMed] [Google Scholar]
  9. Freedom R. M., Olley P. M., Coceani F., Rowe R. D. The prostaglandin challenge. Test to unmask obstructed total anomalous pulmonary venous connections in asplenia syndrome. Br Heart J. 1978 Jan;40(1):91–94. doi: 10.1136/hrt.40.1.91. [DOI] [PMC free article] [PubMed] [Google Scholar]
  10. Hastreiter A. R., van der Horst R. L., Sepehri B., DuBrow I. W., Fisher E. A., Levitsky S. Prostaglandin E1 infusion in newborns with hypoplastic left ventricle and aortic atresia. Pediatr Cardiol. 1982;2(2):95–98. doi: 10.1007/BF02424943. [DOI] [PubMed] [Google Scholar]
  11. Heymann M. A., Berman W., Jr, Rudolph A. M., Whitman V. Dilatation of the ductus arteriosus by prostaglandin E1 in aortic arch abnormalities. Circulation. 1979 Jan;59(1):169–173. doi: 10.1161/01.cir.59.1.169. [DOI] [PubMed] [Google Scholar]
  12. Horton E. W., Main I. H., Thompson C. J., Wright P. M. Effect of orally administered prostaglandin E1 on gastric secretion and gastrointestinal motility in man. Gut. 1968 Dec;9(6):655–658. doi: 10.1136/gut.9.6.655. [DOI] [PMC free article] [PubMed] [Google Scholar]
  13. Kitterman J. A., Liggins G. C., Fewell J. E., Tooley W. H. Inhibition of breathing movements in fetal sheep by prostaglandins. J Appl Physiol Respir Environ Exerc Physiol. 1983 Mar;54(3):687–692. doi: 10.1152/jappl.1983.54.3.687. [DOI] [PubMed] [Google Scholar]
  14. Lewis A. B., Freed M. D., Heymann M. A., Roehl S. L., Kensey R. C. Side effects of therapy with prostaglandin E1 in infants with critical congenital heart disease. Circulation. 1981 Nov;64(5):893–898. doi: 10.1161/01.cir.64.5.893. [DOI] [PubMed] [Google Scholar]
  15. Lewis A. B., Takahashi M., Lurie P. R. Administration of prostaglandin E1 in neonates with critical congenital cardiac defects. J Pediatr. 1978 Sep;93(3):481–485. doi: 10.1016/s0022-3476(78)81171-8. [DOI] [PubMed] [Google Scholar]
  16. Neutze J. M., Starling M. B., Elliott R. B., Barratt-Boyes B. G. Palliation of cyanotic congenital heart disease in infancy with E-type prostaglandins. Circulation. 1977 Feb;55(2):238–241. doi: 10.1161/01.cir.55.2.238. [DOI] [PubMed] [Google Scholar]
  17. Olley P. M., Coceani F., Bodach E. E-type prostaglandins: a new emergency therapy for certain cyanotic congenital heart malformations. Circulation. 1976 Apr;53(4):728–731. doi: 10.1161/01.cir.53.4.728. [DOI] [PubMed] [Google Scholar]
  18. Sankaran K., Conly J., Boyle C. A., Tyrrell M. Intestinal colic and diarrhea as side effects of intravenous alprostadil administration. Am J Dis Child. 1981 Jul;135(7):664–665. doi: 10.1001/archpedi.1981.02130310068023. [DOI] [PubMed] [Google Scholar]
  19. Schöber J. G., Kellner M., Mocellin R., Schumacher G., Bühlmeyer K. Indications and pharmacological effects of therapy with prostaglandin E1 in the newborn. Adv Prostaglandin Thromboxane Res. 1980;7:905–911. [PubMed] [Google Scholar]
  20. Silove E. D. Administration of E-type prostaglandins in ductus-dependent congenital heart disease. Pediatr Cardiol. 1982;2(4):303–305. doi: 10.1007/BF02426977. [DOI] [PubMed] [Google Scholar]
  21. Silove E. D., Coe J. Y., Shiu M. F., Brunt J. D., Page A. J., Singh S. P., Mitchell M. D. Oral prostaglandin E2 in ductus-dependent pulmonary circulation. Circulation. 1981 Mar;63(3):682–688. doi: 10.1161/01.cir.63.3.682. [DOI] [PubMed] [Google Scholar]
  22. Starling M. B., Neutze J. M., Elliott R. L., Elliott R. B. Studies on the effects of prostaglandins E1, E2, A1, and A2 on the dustus arteriosus of swine in vivo using cineangiography. Prostaglandins. 1976 Sep;12(3):355–367. doi: 10.1016/0090-6980(76)90016-2. [DOI] [PubMed] [Google Scholar]

Articles from Archives of Disease in Childhood are provided here courtesy of BMJ Publishing Group

RESOURCES